



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 4.96                       |
| Trade Time:   | 4:00 PM ET<br>May 18, 2018 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 3.75 - 6.50                |
| Volume        | N/A                        |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

## Stock Performance



## Press Releases [\[ View all \]](#)

May 2, 2018

[Endologix Appoints John Onopchenko as Chief Executive Officer](#)

May 2, 2018

[Endologix Reports First Quarter 2018 Financial Results](#)

Apr 25, 2018

[Endovascular Aneurysm Sealing \(EVAS\) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair \(EVAR\) in New Study](#)

Apr 3, 2018

[Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018](#)

Mar 19, 2018

[Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair \(EVAR\) Using Ovation Abdominal Stent Graft Systems](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

Mar 13, 2018

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2018

[Quarterly Report \(10-Q\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)